Kimia Biosciences Peer Comparison

BSE: 530313

₹30.86

₹1.47 (5.00%)

As on 21-Sep-2026IST

Market cap

₹146 Cr

Revenue (TTM)

₹112 Cr

P/E Ratio

20.3

P/B Ratio

8.1

Div. Yield

0 %

Edit

	Kimia Biosciences	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Market cap (₹ Cr)	146	20,956	20,944	17,950	18,477
Revenue (₹ Cr)	112	2,287	1,682	3,230	2,570
Net Profit (₹ Cr)	7.19	678.07	273.51	666.92	735.15
Net Margin (%)	6.37	28.10	16.19	20.60	26.88
RoE (%)	49.04	19.73	11.15	18.75	19.16
Price to Earnings	20.32	31.50	70.44	27.88	25.13
Price-To-Book	8.08	5.71	7.80	4.45	4.19

Income Statement (₹ Cr)

	Kimia Biosciences	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Operating Revenue	112.02	2,287.33	1,682.47	3,229.67	2,569.77
Total Income	112.88	2,413.29	1,689.83	3,237.12	2,735.39
Total Expenditure	97.94	1,490.75	1,203.91	2,090.06	1,628.14
EBITDA	14.09	796.58	478.55	1,139.61	941.63
Depreciation	4.09	78.10	126.01	281.06	57.58
EBIT	10.00	718.48	352.55	858.55	884.05
Interest	2.60	0.88	52.11	190.64	7.69
Other Income	0.86	125.96	7.37	7.45	165.62
Exceptional Items	0.00	0.00	12.16	-17.24	-49.16
Profit before Tax	8.26	843.56	319.96	658.12	992.82
Provision for Tax	1.07	165.49	46.45	-8.80	257.67
Profit after Tax	7.19	678.07	273.51	666.92	735.15

	Kimia Biosciences	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Shareholder's Funds	17.72	3,586.42	2,591.20	3,902.67	4,202.90
Minority Interest	0.00	-12.71	0.00	-21.81	0.00
Non-Current Liabilities	24.29	28.74	266.35	1,392.75	91.50
Current Liabilities	61.18	385.94	848.06	2,077.10	627.48
Total Liabilities	111.21	3,207.85	3,310.68	6,865.52	4,911.11

	Kimia Biosciences	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Non-Current Assets	37.97	1,291.22	2,525.44	5,617.77	770.28
Current Assets	63.62	2,585.66	1,109.77	1,539.85	3,803.22
Total Assets	111.21	3,207.85	3,310.68	6,865.52	4,911.11
Total Debt*	32.57	0.55	586.37	2,421.66	2.50
Net Current Assets	2.44	2,199.72	261.71	-537.25	3,175.74
Contingent Liabilities	0.12	0.64	76.22	51.96	363.79

	Kimia Biosciences	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Cash From Operating Activities	21.31	432.37	132.27	1,065.01	659.75
Cash Flow from Investing Activities	-4.70	-334.73	-199.13	-79.97	-71.34
Cash from Financing Activities	-16.55	-38.32	62.65	-881.32	-205.34
Net Cash Inflow / Outflow	0.06	59.32	-4.21	103.72	383.07

	Kimia Biosciences	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
ROCE (%)	42.18	26.22	6.95	13.59	26.21
ROE (%)	49.04	19.73	11.15	18.75	19.16
ROA (%)	13.92	18.69	7.80	9.26	14.95
EBIT Margin (%)	8.93	31.41	20.95	26.58	34.40
Net Margin (%)	6.37	28.10	16.19	20.60	26.88
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Kimia Biosciences	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Revenue Growth (%)	-6.73	15.01	27.91	9.59	10.69
EBIT Growth (%)	-36.11	18.45	58.32	16.84	24.14
Net Profit Growth (%)	-18.17	19.61	149.56	62.68	-9.09
EPS Growth (%)	-18.17	17.73	-3.57	67.41	14.40
Book Value Growth (%)	2,910.91	23.77	30.63	10.19	17.30

	Kimia Biosciences	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Price / Earnings	20.32	31.50	74.73	27.20	23.95
Price / Book Value	8.08	5.71	7.80	4.45	4.19
Dividend Yield (%)	0.00	0.29	0.06	0.00	1.86
EV/EBITDA	12.63	25.04	45.05	17.72	16.32
Market Cap (₹ Cr)	201.13	15,219.80	6,484.12	19,292.77	18,318.10

	Kimia Biosciences	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Debt to Equity	1.29	0.00	0.07	0.24	0.00
Short term debt to equity ratio	1.97	0.00	0.13	0.14	0.00
Current Ratio	1.04	6.70	1.31	0.74	6.06
Quick Ratio	0.61	5.59	0.88	0.53	5.31
Interest Coverage	4.18	959.59	7.14	4.45	130.11

	Kimia Biosciences	Caplin Point Lab	Shilpa Medicare	Eris Lifesciences	Pfizer
Debtors to sales (%)	26.17	36.10	30.84	21.07	7.07
Asset Turnover	2.17	0.63	0.48	0.45	0.52
Receivable days	98.68	110.70	118.15	54.06	29.10
Inventory Days	100.34	65.86	98.29	32.16	69.53
Payable days	233.00	105.88	128.16	140.91	76.77
Cash Conversion Cycle	-33.97	70.68	88.28	-54.69	21.86

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.